Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04450836 | Nov 2020 → Mar 2024 | colorectal cancer | UNICANCER | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450836 ↗ |
| Route | Oral | “TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally” NCT04450836 ↗ |